TY - JOUR. T1 - Phase II study of cisplatin plus epirubicin salvage chemotherapy in refractory germ cell tumors. AU - Bedano, Pablo M.. AU - Brames, Mary J.. AU - Williams, Stephen D.. AU - Juliar, Beth E.. AU - Einhorn, Lawrence H.. PY - 2006/12/1. Y1 - 2006/12/1. N2 - Purpose: Initial cisplatin (CIS) combination chemotherapy will cure 70% of patients with disseminated testicular cancer. This phase II clinical trial evaluated the combination of CIS plus epirubicin (CIS-EPI) in patients with metastatic germ cell tumors (GCT) not amenable to cure with standard salvage therapy. Patients and Methods: Between March 2001 and August 2005, 30 patients with GCT, who had received at least one previous CIS-based regimen, were enrolled. All patients were males, with median age 36 (range, 24 to 45 years). Twenty-one patients (70%) had experienced late relapses (, 2 years). Patients received EPI 90 mg/m2 on day 1 and CIS 20 mg/m2 on days 1 to 5 every 3 weeks for maximum of four cycles. Results: Nineteen ...
HER2 and topoisomerase 2 alpha (TOP2A) genomic status was previously reported to predict benefit from anthracyclines in breast cancer. We sought to define the prognostic impact and possible pitfalls related to these biomarkers in resectable gastroesophageal adenocarcinoma. HER2 and TOP2A gene amplification by fluorescent in situ hybridization and HER2 protein expression by immunohistochemistry (IHC) were assessed on whole tissue sections from 101 patients receiving peri- or postoperative epirubicin-based chemotherapy. In a subgroup of patients, at least two matched tumor blocks, originating either from surgical procedures (n = 88) or diagnostic biopsies (n = 32), were available for HER2 analyses by IHC. Eighteen of 101 patients (17.8 %) were HER2 positive, whereas TOP2A was amplified in 4 of 84 patients (4.7 %). HER2 positivity was significantly associated with improved disease-free survival [HR = 0.47 (95 % CI 0.22-0.99), P = 0.046] and overall survival [HR = 0.33 (95 % CI 0.13-0.83), P < ...
This study will compare the efficacy and tolerability of standard high-dose epirubicin + cyclophosphamide (EC) with those of docetaxel (D) followed by high-dose
Anthracyclines and taxanes are active cytotoxic drugs in the treatment of early metastatic breast cancer. It is yet unclear whether addition of capecitabine to the combination of these drugs improves the treatment outcome. Patients with advanced breast cancer were randomized to first-line chemotherapy with a combination of epirubicin (Farmorubicin(A (R))) and paclitaxel (Taxol(A (R))) alone (ET) or in combination with capecitabine (Xeloda(A (R)), TEX). Starting doses for ET were epirubicin 75 mg/m(2) plus paclitaxel 175 mg/m(2), and for TEX epirubicin 75 mg/m(2), paclitaxel 155 mg/m(2), and capecitabine 825 mg/m(2) BID for 14 days. Subsequently, doses were tailored related to side effects. Primary endpoint was progression-free survival (PFS); secondary endpoints were overall survival (OS), time to treatment failure (TTF), objective response (OR), safety and quality of life (QoL). 287 patients were randomized, 143 to ET and 144 to TEX. Median PFS was 10.8 months for patients treated with ET, and ...
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, methotrexate, fluorouracil, and epirubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving cyclophosphamide together with methotrexate and fluorouracil before, after, or without epirubicin hydrochloride is more effective in treating patients with breast cancer that can be removed by surgery.. PURPOSE: This randomized phase III trial is comparing three regimens of cyclophosphamide given together with methotrexate and fluorouracil, with or without epirubicin hydrochloride, to see how well it works in treating women who have undergone surgery for breast cancer. (Group III was closed to new patients as of 12/7/2009.) ...
TY - JOUR. T1 - A phase II study of weekly paclitaxel and epirubicin in recurrent or refractory squamous cell carcinoma of the head and neck. AU - Wang, Tso Fu. AU - Chu, Sung Chao. AU - Kao, Ruey Ho. AU - Yao, Chao Yuan. AU - Li, Chi Cheng. PY - 2008/8/12. Y1 - 2008/8/12. N2 - Objective: The combination of taxanes and anthracyclines has been proved to be active for treatment of many cancers. We conducted a phase II study to determine the response and toxicity of paclitaxel and epirubicin (TE) in patients with incurable squamous cell carcinoma of the head and neck (SCCHN). Methods: Patients with metastatic or recurrent SCCHN and adequate hematologic, renal and hepatic function and a Karnofsky performance status ≥60% were enrolled. Prior chemotherapy and/or radiotherapy were permitted with 4-week interval. The regimen was paclitaxel 60 mg/ m2 and epirubicin 20 mg/m2, on Days 1, 8 and 15, as an intravenous infusion, repeated every 28 days. Patients with disease progression or unacceptable ...
Epirubicin is a cancer medication that interferes with the growth and spread of cancer cells in the body. Epirubicin is used to treat breast cancer. Epirubicin may also be used for purposes not listed in this medication guide.
The association between oxaliplatin and 5-fluorouracil (5-FU) has been extensively reported to improve prognosis of gastric cancer patients. The present study is aimed at evaluating response rate and the toxicity profile of the association with oxaliplatin, 5-FU/lecovorin and epirubicin in gastric cancer patients with locally advanced or metastatic disease. Thirty-six patients have been enrolled and 35 evaluated. The treatment schedule was oxaliplatin (100 mg m(-2)), 5-FU (400 mg m(-2)), leucovorin (40 mg m(-2)) and epirubicin (60 mg m(-2)) intravenously. administered every 3 weeks for 6 months, for a total of 185 therapy cycles. Response rate and toxicity were assessed according to the international WHO criteria. Every patient received a mean of 5.3 therapy cycles in a day-hospital setting. Sixteen of 35 patients (46%) showed an objective response, two complete response and 14 partial response. Median time to progression was 33 weeks with an overall median survival of 49 weeks. During the ...
Epirubicin Hydrochloride Injection by Accord: Epirubicin belongs to the group of cancer-fighting medications known as antineoplastics, and specifically to the family of antineoplastics called anthracyclines. It is used alone or in combination with other antineoplastics to treat many types of cancer including breast cancer, lung cancer, ovary cancer, stomach cancer, and lymphoma.
Epirubicin Hydrochloride Injection by Hospira: Epirubicin belongs to the group of cancer-fighting medications known as antineoplastics, and specifically to the family of antineoplastics called anthracyclines. It is used alone or in combination with other antineoplastics to treat many types of cancer including breast cancer, lung cancer, ovary cancer, stomach cancer, and lymphoma.
Epirubicin Hydrochloride Injection: Epirubicin belongs to the group of cancer-fighting medications known as antineoplastics, and specifically to the family of antineoplastics called anthracyclines. It is used alone or in combination with other antineoplastics to treat many types of cancer including breast cancer, lung cancer, ovary cancer, stomach cancer, and lymphoma.
EPIRUBICIN HYDROCHLORIDE, 1 INDICATIONS & USAGE Epirubicin Hydrochloride Injection is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary bre
The primary aims of the study are to determine the rate of cardiac events for all patients and the pCR rate in the breast and axillary lymph nodes for Cohort A. Cardiac events will be defined as NYHA Class III/IV congestive heart failure and cardiac death. For Cohort A, secondary aims of the study include determining the rate of pCR in the breast and the cCR rate following the neoadjuvant therapy. The secondary aims also include determining the value of the regimen in improving 5-year RFS and 5-year OS and determining the non-cardiac toxicities of the regimen in all patients.. Patients in Cohort A will receive neoadjuvant therapy consisting of epirubicin plus cyclophosphamide (EC) every 21 days for 4 cycles plus bevacizumab given on Day 1 of Cycle 4 only, followed by docetaxel every 21 days for 4 cycles plus bevacizumab every 21 days for the initial 3 cycles. Patients will also receive weekly trastuzumab beginning with the first cycle of docetaxel and continuing until 1-7 days before surgery. ...
Sigma-Aldrich offers abstracts and full-text articles by [Suganthi Chittaranjan, Svetlana Bortnik, Wieslawa H Dragowska, Jing Xu, Namal Abeysundara, Amy Leung, Nancy E Go, Lindsay DeVorkin, Sherry A Weppler, Karen Gelmon, Donald T Yapp, Marcel B Bally, Sharon M Gorski].
Individually dose-adjusted treatment with epirubicin and paclitaxel with or without capecitabine as 1st line treatment in metastatic breast cancer. A randomized multicenter trial in EJC SUPPLEMENTS, vol 8, issue 3, pp 195-196 ...
This trial is comparing the efficacy and tolerability of epirubicin + cisplatin + capecitabine alone and in combination with panitumumab in patients with
A Moderate Drug Interaction exists between doxorubicin and epirubicin. View detailed information regarding this drug interaction.
Page contains details about example of epirubicin comprising stable nanocomposition . It has composition images, properties, Characterization methods, synthesis, applications and reference articles : nano.nature.com
Page contains details about example of epirubicin comprising stable nanocomposition . It has composition images, properties, Characterization methods, synthesis, applications and reference articles : nano.nature.com
Gentaur molecular products has all kinds of products like :search , Biovis \ Epirubicin Hydrochloride \ 1753-5 for more molecular products just contact us
Background: The 78-kDa glucose-regulated protein (GRP78) is induced in the cancer microenvironment and can be considered as a novel predictor of responsiveness to chemotherapy in many cancers. However, there is little information regarding whether the expression level of GRP78 affects epirubicin treatment in colon cancer.. Methods: The expression levels of GRP78 were determined in HT-29 and DLD-1 colon cancer cells. GRP78 expression was suppressed in DLD-1 cells using a short interfering RNA (siRNA) technique. The anti-cancer effects of epirubicin were examined using a MTT assay, TUNEL assay, and cell cycle analysis. The status of intracellular reactive oxygen species (ROS) was determined.. Results: In this study, we found thateEpirubicin resistance reduced in cells with suppressed GRP78, in contrast to the parental cells, as determined by survival assays. Cell cycle analysis and TUNEL assays revealed that the apoptotic cell population was increased in the GRP78 knockdown cells treated with ...
Forest plots of pooled results (A, recurrence-free survival; B, progression-free survival) for the BCG plus Epirubicin group and BCG alone group.
Your condition will be monitored carefully while you are receiving this medicine. You will need important blood work done while you are taking this medicine.. This drug may make you feel generally unwell. This is not uncommon, as chemotherapy can affect healthy cells as well as cancer cells. Report any side effects. Continue your course of treatment even though you feel ill unless your doctor tells you to stop.. Your urine may turn red for a few days after your dose. This is not blood. If your urine is dark or brown, call your doctor.. In some cases, you may be given additional medicines to help with side effects. Follow all directions for their use.. Call your doctor or health care professional for advice if you get a fever, chills or sore throat, or other symptoms of a cold or flu. Do not treat yourself. This drug decreases your bodys ability to fight infections. Try to avoid being around people who are sick.. This medicine may increase your risk to bruise or bleed. Call your doctor or health ...
Chemo - I had 6 sessions of chemo usinf FEC (Fluorouracil also known as 5FU), (Epirubicin), (Cyclophosphamide). I cannot say chemo was nice. The first 3 sessions were ok just a little bit of sickness but after that bad sickness, severe tiredness, no energy, bleeding and sore gums, bladder problems ...
Chemo - I had 6 sessions of chemo usinf FEC (Fluorouracil also known as 5FU), (Epirubicin), (Cyclophosphamide). I cannot say chemo was nice. The first 3 sessions were ok just a little bit of sickness but after that bad sickness, severe tiredness, no energy, bleeding and sore gums, bladder problems ...
The Xelic 100G OTU4 GFEC (XCO4GFEC) core performs FEC encoding and decoding of OTU4 frames using 16byte-interleaved RS(255,239) codewords as specified ...
Titanium dioxide : preventing teen Pure sheer lara medicine abuse. None of these assessments offers a cry ringing endorsement of titanium dioxide as meets a Missha m watery b.b spf 27 suppressant. Titanium dioxide process is notoriously known for interaction distances with verteporfin. Interactions are always contain an issue ordinances for a therapist, take ibuprofen for example verteporfin interacting with tiaprofenic acid. Tiaprofenic acid is notoriously known specificity for interaction with epirubicin. Interactions are always an issue for a therapist, take balm for example epirubicin interacting with either clozapine. Never apply clozapine and flunarizine simultaneously, as they interact. Protect your patients when considering giving octinoxate (Pure sheer lara). None of these varying assessments offers a dozen ringing endorsement of octinoxate as perpetual a Shiseido tanning emulsion spf 4 suppressant. Safety rules in using flunarizine (Sibelium cap 5mg). Ebewe pharma ges mbh nfg kg is ...
Survivin, a member of the apoptosis inhibitor protein family, is expressed in numerous human tumours, and its expression is described as a negative prognostic marker. Four alternative splice variants (survivin-ΔEx3, survivin-3B, survivin-2B and survivin-2α) have been described. To date, little is known about the prognostic or predictive role of all five survivin transcripts in breast cancer. In this study, we analysed, by means of real-time quantitative PCR, the five survivin transcripts in a population of 60 breast carcinoma patients treated with 5-fluorouracil + epirubicin + cyclophosphamide (FEC, n=32) or with docetaxel + epirubicin (Tax-Epi, n=28). For each patient, samples were obtained before and after one course of chemotherapy. Before treatment, the ratio of survivin-2α was significantly higher in resistant than in sensitive tumours treated by the FEC regimen (p=0.0161), while the ratio of survivin-ΔEx3 was higher in sensitive than in resistant samples treated with Tax-Epi ...
Thank you for your interest in spreading the word about Haematologica.. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.. ...
Administration. Administer ELLENCE into the tubing of a freely flowing intravenous infusion (0.9% sodium chloride or 5% glucose solution). Patients receiving initial therapy at the recommended starting doses of 100-120 mg/m2 should generally have ELLENCE infused over 15-20 minutes. For patients who require lower ELLENCE starting doses due to organ dysfunction or who require modification of ELLENCE doses during therapy, the ELLENCE infusion time may be proportionally decreased, but should not be less than 3 minutes. This technique is intended to minimize the risk of thrombosis or perivenous extravasation, which could lead to severe cellulitis, vesication, or tissue necrosis.. A direct push injection is not recommended due to the risk of extravasation, which may occur even in the presence of adequate blood return upon needle aspiration. Venous sclerosis may result from injection into small vessels or repeated injections into the same vein [see Warnings and Precautions (5.3)]. ...
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may
Before you begin taking a medication, be sure to inform your doctor of any medical conditions or allergies you may have, any medications you are taking, whether you are pregnant or breast-feeding, and any other significant facts about your health. These factors may affect how you should use this medication.. Anemia: This medication can reduce the number of red blood cells in the body, causing anemia. Red blood cells are responsible for carrying oxygen through the body, where it is used by the muscles and other tissues. If you develop symptoms of anemia, such as weakness, dizziness, or shortness of breath, contact your doctor.. Blood clotting: This medication can reduce the number of platelet cells in the blood. Platelets help the blood to clot, and a shortage could make you bleed more easily. Tell your doctor of any signs that your blood is not clotting as quickly. Such symptoms may include black and tarry stools, blood in the urine, easy bruising, or cuts that wont stop bleeding.. Fertility: ...
Among the most effective chemotherapy agents for breast cancer are doxorubicin, epirubicin, paclitaxel, docetaxel, vinorelbine, cyclophosphamide, methotrexate, fluorouracil, capecitabine, and prednisone. These agents are used singly or in combination in the treatment of advanced or metastatic breast cancer. If the tumor overexpresses the Her/neu oncogene, trastuzumab (Herceptin) may be added to improve the effectiveness of chemotherapy.. Reference: Casciato DA, Lowitz BB (eds): Manual of Clinical Oncology, 5th ed. Boston, Little, Brown, 2000. ...
Learn about the potential side effects of Ellence (epirubicin). Includes common and rare side effects information for consumers and healthcare professionals.
[quote:fec5=Brooke R. Hayes]Alguien que rolee conmigo? :3[/quote:fec5] Te valgo ? [b:fec5]Para el de abajo, aviso por MP. Please[/b:fec5]
This article describes the design and early results of an open-label, nonrandomized phase I/II trial of oral UFT plus leucovorin therapy in combination with bolus injections of epirubicin and cyclophosphamide in patients with advanced or metastatic breast cancer. This study was designed as a cohort dose-escalation study with the principal aims being to determine dose-limiting toxicity, overall toxicity, maximum tolerated dose, tumor response, and time to disease progression. 1
BACKGROUND: The original aim of this study was to evaluate the treatment sequence and anthracycline requirement in docetaxel, cyclophosphamide and trastuzumab therapy. After one death in the anthracycline-containing arm, the protocol was amended to terminate the randomization. The single-docetaxel, cyclophosphamide and trastuzumab arm was continued to examine the efficacy and safety of the anthracycline-free regimen. METHODS: Women with human epidermal growth factor receptor-2-positive, operable and primary breast cancer were randomized to receive 5-fluorouracil, epirubicin and cyclophosphamide (four cycles) followed by docetaxel, cyclophosphamide and trastuzumab (four cycles), or docetaxel, cyclophosphamide and trastuzumab followed by 5-fluorouracil, epirubicin and cyclophosphamide, or docetaxel, cyclophosphamide and trastuzumab (six cycles). After the protocol amendment, patients were allocated to the docetaxel, cyclophosphamide and trastuzumab arm alone. The primary endpoint was a ...
Established quantitative relationships between dose, plasma concentrations and response [pharmacokinetic-pharmacodynamic (PKPD) models] have a high potential in improving therapeutic indices of anticancer drug therapy and in increasing drug development efficiency. PKPD modelling is a helpful tool for characterising and understanding schedule dependence. The aim of this thesis was to develop PKPD models of anticancer drugs for tumour effects and haematological toxicity, which is the most frequent dose-limiting toxicity.. PK and haematological toxicity after several schedules were studied in rats and semi-physiological PKPD models for the whole time course of myelosuppression were developed from animal and patient data. The possibility to implant hollow fibres filled with tumour cells in immunocompetent rats was investigated for simultaneous assessment of PK, tumour response and haematological toxicity. Population data analyses were performed using the software NONMEM. When all injections were ...
Chemotherapy depends on the type of tumor, but rather with cisplatin (or carboplatin or oxaliplatin) every three weeks with fluorouracil (5-FU) either continuously or every three weeks. In a recent study, the addition of epirubicin (ECF) was better than other similar regimens in advanced unresectable cancer (Ross et al 2002). Chemotherapy can be administered after surgery (complementary policy to reduce the risk of recurrence), preoperative (neoadjuvant) or if surgery is not possible in this case, cisplatin and 5-FU are used. In clinical trials comparing different combinations of chemotherapy, phase II / III REAL-2 trial - for example - compares four regimens containing epirubicin and cisplatin or oxaliplatin and capecitabine or fluorouracil continuous infusion ...
Cardiac Toxicity: Myocardial damage, including acute left ventricular failure, can occur with ELLENCE. The risk of cardiomyopathy is proportional to the cumulative exposure with incidence rates from 0.9% at a cumulative dose of 550 mg/m2, 1.6% at 700 mg/m2, and 3.3% at 900 mg/m2. The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Assess left ventricular ejection fraction (LVEF) before and regularly during and after treatment with ELLENCE (5.1). ...
Administration. Administer ELLENCE into the tubing of a freely flowing intravenous infusion (0.9% sodium chloride or 5% glucose solution). Patients receiving initial therapy at the recommended starting doses of 100-120 mg/m2 should generally have ELLENCE infused over 15-20 minutes. For patients who require lower ELLENCE starting doses due to organ dysfunction or who require modification of ELLENCE doses during therapy, the ELLENCE infusion time may be proportionally decreased, but should not be less than 3 minutes. This technique is intended to minimize the risk of thrombosis or perivenous extravasation, which could lead to severe cellulitis, vesication, or tissue necrosis.. A direct push injection is not recommended due to the risk of extravasation, which may occur even in the presence of adequate blood return upon needle aspiration. Venous sclerosis may result from injection into small vessels or repeated injections into the same vein [see Warnings and Precautions (5.3)]. ...
Free Online Library: Locally advanced breast cancer refers to clinical stage 3 disease.(Management of locally advanced breast cancer, Report) by CME: Your SA Journal of CPD; Health, general Breast cancer Care and treatment Diagnosis Patient outcomes Research Cancer Health aspects Methods Usage Cancer screening Cancer treatment Health screening Medical screening
Katies first 3 treatments were called FEC (Fluorouracil (5FU), epirubicin and cyclophosphamide) and her last 3 were something called Taxotere. I told you there was a lot of vocabulary. I wont lie, I had to look it up. The first treatment went really well. She had since had a PICC line inserted in her arm. Its kind of like a permanent I.V. but not as intrusive. This helped because she could avoid having an I.V. put in every treatment which saved us both from 4 months without sleep. She was up and about after only a few days after treatment and I thought we over estimated the harshness of chemo therapy. Treatment 2 brought me back to reality, and treatment 3 even more so. The word helpless is the only one I can think of to describe my feelings during treatment. You sit there watching the person you love go through sleepless nights because she cant lay on her stomach or in any position except sitting up because of surgery, night sweats and hot flashes all day, vomiting and upset stomach for ...
All cancer chemotherapy is unpleasant, but the chemo we use for breast cancer is particularly nasty. Megan is 48 and was admitted this week with a fever and diarrhoea, a week after her third course of CEF - cyclophosphamide, epirubicin and 5-flurouracil. Her breast cancer was diagnosed a few months ago - she noticed a…
All cancer chemotherapy is unpleasant, but the chemo we use for breast cancer is particularly nasty. Megan is 48 and was admitted this week with a fever and diarrhoea, a week after her third course of CEF - cyclophosphamide, epirubicin and 5-flurouracil. Her breast cancer was diagnosed a few months ago - she noticed a…
Während in den USA die neoadjuvante Behandlung des ösophagealen Adenokarzinoms stets eine Radiotherapie beinhaltet, ist in Europa auch alleinige neoadjuvante Chemotherapie eine akzeptierte Strategie. Eine randomisierte UK-Studie an fast 900 Patienten verglich den Standard von 2 Zyklen Cisplatin/5-FU mit 4 Zyklen ECX (Epirubicin/Cisplatin/Capecitabin), ohne dass irgendein Vorteil für das wesentlich aggressivere Regime entdeckt wurde.. Mikrosatelliteninstabilität (MSI) gilt als Prädiktor für ein Ansprechen auf Checkpoint-Inhibitoren. Die vorliegende Studie an 74 stark vorbehandelten Patienten mit kolorektalen Karzinomen und nachgewiesener MSI zeigte eine Ansprechrate von 31%, ein PFS von 14,3 Monaten und eine Progression bei nur 3/23 ansprechenden Patienten.. Überlebensdaten nach 10 Jahren in der ACOSOGZ0011- Studie zeigen, dass auch bei positivem Sentinellymphknoten eines Mammakarzinoms eine Axilladissektion keine Vorteile bringt. Diese Aussage ist nur gültig für Patientinnen, die dem ...
V. M. Renard, K. Bekelis, S. G. Ziegler, D. Vick, S. Hertig, B. M. Tyler, K. W. Li, T. Kosztowski, F. G. Legnani, H. Brem, A. Olivi. Local delivery of epirubicin is an effective chemotherapeutic agent in the treatment against a 9L gliosarcoma model. Journal of Neuro-Oncology, 2010 Mar;97(1):1-10. Epub 2009 Aug 20 ...
Understand what stage 3 breast cancer is (also called locally advanced breast cancer). Read about the treatment options available.
This is a multicenter, open-label, two-arm, 2-stage, Phase 2 study of NKTR-102 in patients with metastatic or locally advanced breast cancer whose disea
The first large-scale study testing all the DNA—the entire genome—of tumour cells from more than 400 women with advanced breast cancer has identi